title: Actigraphic sleep-wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer's disease.
abstract: Recent studies suggest melatonin, due to its antioxidant and free-radical-scavenging actions, may play a role in the neuroprotection against amyloid, which is implicated in the pathogenesis of Alzheimer's disease (AD). In this study, we determined urinary 6-sulfatoxymelatonin (aMT6s) excretion together with actigraphic sleep-wake patterns of untreated male patients with AD who lived at home. Results were compared with those obtained from normal age-matched elderly and normal young male subjects. Similar measurements were also performed in another group of patients with AD who were treated with a cholinesterase inhibitor (Donepezil, Aricept). Total 24h aMT6s values were significantly reduced in elderly controls (19.9h +/- 5.2 microg/ 24h), in those with untreated AD (12.7 +/- 4.4 microg/24h), and in patients treated for AD (12.4 +/- 4.4 microg/24h) compared with normal young men (32.8 +/- 3.1 microg/24h). A day-night difference in aMT6s was evident in all young controls, in 50% of elderly controls, in only 20% of patients with untreated AD, and in 67% of those with AD receiving Aricept. Sleep quality (expressed as sleep efficiency, wake time, and long undisturbed sleep duration) was better in young and elderly controls compared with the two groups of patients with AD. There was no significant correlation between aMT6s values or sleep patterns and the severity of cognitive impairment in patients with AD. Taken together, these data suggest that disrupted sleep, decreased melatonin production, and partial lack of day-night difference in melatonin secretion were observed equally in normal elderly and in patients with AD. Our results do not permit drawing any conclusion as to whether changes in urinary aMT6s excretion is correlated with disturbed sleep in patients with AD.
authors.affiliation: Endocrine Institute, Haemek Medical Center, Afula, Israel.
authors.forename: R
authors.initials: R
authors.lastname: Luboshitzky
authors.forename: Z
authors.initials: Z
authors.lastname: Shen-Orr
authors.forename: O
authors.initials: O
authors.lastname: Tzischichinsky
authors.forename: M
authors.initials: M
authors.lastname: Maldonado
authors.forename: P
authors.initials: P
authors.lastname: Herer
authors.forename: P
authors.initials: P
authors.lastname: Lavie
mesh_terms: D000328:Adult; D000368:Aged; D000375:Aging; D000544:Alzheimer Disease / Q000503:physiopathology*; D002940:Circadian Rhythm / Q000502:physiology*; D003704:Dementia; D005260:Female; D006801:Humans; D008027:Light; D008297:Male; D008550:Melatonin / Q000031:analogs & derivatives* / Q000652:urine*; D008875:Middle Aged; D017286:Polysomnography / Q000379:methods*; D012890:Sleep / Q000502:physiology*; D013997:Time Factors
chemical_list: C054513:6-sulfatoxymelatonin; D008550:Melatonin